MARKET

KTTA

KTTA

Pasithea Therapeutics Corp
NASDAQ
0.7801
-0.0141
-1.78%
After Hours: 0.7839 +0.0038 +0.49% 19:18 05/15 EDT
OPEN
0.8000
PREV CLOSE
0.7942
HIGH
0.8150
LOW
0.7801
VOLUME
549.55K
TURNOVER
--
52 WEEK HIGH
2.060
52 WEEK LOW
0.2810
MARKET CAP
19.46M
P/E (TTM)
-0.2685
1D
5D
1M
3M
1Y
5Y
1D
Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate
Benzinga · 21h ago
Weekly Report: what happened at KTTA last week (0504-0508)?
Weekly Report · 5d ago
Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan
PUBT · 05/05 20:46
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
TipRanks · 05/04 23:03
Pasithea Therapeutics appoints chief medical officer
Seeking Alpha · 05/04 12:34
Pasithea Therapeutics Appoints Kartik Krishnan As CMO
NASDAQ · 05/04 11:37
Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer
TipRanks · 05/04 11:32
Pasithea Therapeutics names Kartik Krishnan chief medical officer
PUBT · 05/04 11:05
More
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTA stock methods without spending real money on the virtual paper trading platform.